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Abstract 
Toxic epidermal necrolysis is a rare but clinically well-described dermatological 
pathology. However, clinical pictures of this disorder in text books do not reflect its 
dynamic evolution. Usually, the desquamative post-bullous stage is represented, 
neglecting the initial bullous stage as well as the skin healing. With one clinical case, we 
provide a day-after-day illustration of the evolution of a patient suffering from toxic 
epidermal necrolysis. During one month, a skin area of a limb was regularly photo-
documented. 
 
Case Report 
A 15-year-old female developed fever, stinging eyes and headache, followed one day 
later by sudden appearance of flaccid blisters on the face with subsequent dissemination 
to more than 70% of the whole integument and development of mucosal erosions. Thirty 
days before, she had been operated on the nose and medicated with cefuroxime (for 8 
days), paracetamol (for approx. 10 days) and metamizol (for approx. 10 days), the latter of 
which was later identified by lymphocyte transformation test as the most likely causative 
compound. Four days before admission, she had taken acetylsalicylic acid and 
paracetamol for flu-like symptoms including conjunctival irritation and rhinitis.  
Upon physical evaluation, disseminated flaccid blisters filled with serous liquid were 
present on 70% of her skin surface. Her eye-, mouth-, pharyngeal- and genital mucosae 
were also affected by erosive lesions. A skin biopsy confirmed the diagnosis of toxic 
epidermal necrolysis (TEN) [1]. The calculated SCORTEN was 1. She received 
intravenous immunoglobulins (IVIGs) [2–4], in total 3 g/kg body weight over three 
consecutive days, hydration and nutritional support as well as careful wound care. Topical 
therapy included silver-coated dressings on erosions, and after reepithelialization, skin 
washes with water and wax emulsion were performed, followed by the application of  
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hydrocortisone 0.5% in hydrophilic unguent. From day 1 after onset of IVIG therapy 
onwards, no new development of blisters was observed. During the clinical course, 
desquamation of dusky areas of skin leaving an intact epidermis below was observed. We 
noted frequent spontaneous bleeding upon changes of the silver-coated dressings during 
reepithelialization period in the second week. The remaining detached skin fragments 
that overlied the progressively regrowing epidermis as of day 7 were progressively shed 
between day 7 and day 28. The patient was discharged from the intensive care unit (ICU) 
at day 28 after admission, with almost complete skin reepithelialization. At the last follow-
up control 6 months later, the patient showed full recovery, except for residual alopecia 
and dry eyes. Multiple areas of hypopigmentation confined to areas of previous epidermal 
detachment were also observed. 
Current Therapeutic Modalities for TEN 
To date, no specific treatment with a high evidence level of efficacy has been reported 
for TEN. The standard of care consists of best supportive therapy in an ICU setting, and 
includes hydroelectrolytic and nutritional support as well as regular wound care and the 
appropriate detection and treatment of infectious complications. Whereas best supportive 
care is an accepted standard of care for TEN patients, none of the specific treatment 
strategies described to date, including IVIG (adequately dosed at 3 g/kg body weight; 
there is an apparent dose dependence, as the reduction in mortality appears to be greatest 
for doses of 3–4 g/kg [4]), corticosteroids, and infliximab, has shown solid evidence in 
support of a survival advantage in TEN patients [5]. To date, only one prospective, 
randomized-controlled clinical trial has been reported in TEN, demonstrating no 
therapeutic benefit for thalidomide in the treatment of TEN [6]. IVIG is a safe therapeutic 
modality that has been shown in several case series to potentially provide a benefit in 
TEN. Controversy as to the exact efficacy does, however, exist [7]. In the recently 
established guideline for the use of high-dose immunoglobulins in dermatology, early 
administration of high-dose immunoglobulins (3 g/kg) is recommended in the lack of 
therapeutic alternatives [8]. Indeed, several published studies reporting the use of IVIG 
for the treatment of TEN have shown this therapy to potentially provide a survival 
benefit. The studies published to date are unfortunately heterogeneous, and often of 
limited size, retrospective nature, and noncontrolled. On the other hand, TEN is a rare 
disease, and randomized prospective controlled studies analyzing the effect of IVIG are 
very difficult to perform, and do not exist to date. Eight of the 11 studies published to date 
reporting the use of IVIG in TEN suggest a positive effect of IVIG on mortality if 
compared to the mortality predicted by SCORTEN where applied, or the 25–35% average 
mortality rate for TEN reported in the literature (table 1). It must be kept in mind, 
however, that as for many other therapies, the total dose (in g/kg body weight) of IVIG 
administered may have an effect on the therapeutic outcome. Indeed, a recent publication 
by Trent et al., analyzing in detail the studies published to date, showed that a dose-
response relationship likely exists: per 1-g/kg increase in IVIG dose, there was an 
observed 4.2-fold increase in patient survival. Moreover, no mortality was observed 
amongst the 30 patients that had received 3 g/kg IVIG or more [7]. Taking into account 
the lack of a proven specific therapy, the severity of TEN, the safety of IVIG, and the data 
to date concerning the efficacy of IVIG in TEN, we are of the opinion that in the absence 
of proven superior therapies, IVIG therapy should be considered in patients with TEN. 
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Table 1. Overview of the published studies on IVIG use including 10 or more patients 
 Viard   
1998 [2] 
Trent  
2003 [9] 
Prins 
2003 [3] 
Campione  
2003 [10] 
Al-Mutairi 
2004 [11] 
Shortt  
2004 [12] 
Tan  
2005 [13] 
Stella  
2007 [14] 
Bachot  
2003 [15] 
Brown 2004 
[16] 
Schneck 
2008 [17] 
Study  PNC RNC RNC PNC PNC RNC RNC RC  PNC RNC RC 
Patients  10 24 48 10 12 16 12 23 34 24 75 
Detach,  % 39 44 45 49 58 65*  – – 19  49  – 
Dose IVIG,  
g/kg 
03  04  03  02  02–5  02.8  02 –  02  01.6  01.9 
(0.7–2.3)
Predicted 
mortality, % 
– 33 
(S) 
– 35 
(S) 
– 38 
(A) 
– 35.8 
(S) 
24 
(S) 
28.6 
(S) 
25 
(S) 
Actual mortality, 
% 
00  04 12 10 00 25 08 26 32 41.7  34 
* Initial rash involving 65 ± 29% TBSA. 
PNC = Prospective, noncontrolled; RNC = retrospective, noncontrolled; RC = retrospective, controlled; S = SCORTEN; A = 
APACHE. 
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